Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $85000.0.

  • Voyager Therapeutics' Cash from Financing Activities rose 50714.29% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 9889.9%. This contributed to the annual value of $114.0 million for FY2024, which is 23887.65% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Cash from Financing Activities stood at $85000.0, which was up 50714.29% from $513000.0 recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Cash from Financing Activities high stood at $112.9 million for Q1 2024, and its period low was $12000.0 during Q1 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $344000.0 (2021), whereas its average is $8.3 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Cash from Financing Activities skyrocketed by 26078333.33% in 2023, and later plummeted by 9992.73% in 2025.
  • Voyager Therapeutics' Cash from Financing Activities (Quarter) stood at $227000.0 in 2021, then increased by 21.59% to $276000.0 in 2022, then soared by 66.67% to $460000.0 in 2023, then grew by 24.78% to $574000.0 in 2024, then tumbled by 85.19% to $85000.0 in 2025.
  • Its Cash from Financing Activities was $85000.0 in Q3 2025, compared to $513000.0 in Q2 2025 and $82000.0 in Q1 2025.